Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octreotide for GI Hemorrhage in HHT and Senile Ectasia
NCT00004327Phase 2Completed
- Sponsor
- National Center for Research Resources
- Start
- Jan 1995
- Modality
- Peptides
01
Overview
Phase 2, open-label, single-arm trial of octreotide in hereditary hemorrhagic telangiectasia (HHT) and ectasia, sponsored by National Center for Research Resources. Primary endpoint: Decrease in Gastrointestinal Bleeding at 1 year. Started Jan 1995; status: completed.
02
Drugs
octreotide
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)ectasia
Beyond the preview
Go deeper on NCT00004327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004327.